CUDC 907

Drug Profile

CUDC 907

Alternative Names: CUDC-907

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Curis
  • Developer Curis; Dana-Farber Cancer Institute; National Cancer Institute (USA)
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action 1-phosphatidylinositol 4-kinase inhibitors; Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Thyroid cancer
  • Phase I CNS cancer; Lymphoma; Solid tumours
  • No development reported Multiple myeloma

Most Recent Events

  • 04 Aug 2017 Interim efficacy data from a phase II trial in Diffuse large B cell lymphoma released by Curis
  • 09 Mar 2017 Pharmacodynamics data from preclinical trial in Diffuse large B cell lymphoma presented at the American Society of Hematology annual meeting (ASH-2016)
  • 22 Dec 2016 National Cancer Institute plans a phase II trial for Thyroid cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule) (NCT03002623)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top